Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
59.22
+0.63 (1.08%)
At close: Sep 17, 2025, 4:00 PM EDT
60.64
+1.42 (2.40%)
Pre-market: Sep 18, 2025, 8:00 AM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts that cover Protagonist Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $70.44, which forecasts a 18.95% increase in the stock price over the next year. The lowest target is $57 and the highest is $80.
Price Target: $70.44 (+18.95%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 4 | 5 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 8 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +35.09% | Sep 17, 2025 |
| Barclays | Barclays | Buy Initiates $72 | Buy | Initiates | $72 | +21.58% | Sep 17, 2025 |
| Leerink Partners | Leerink Partners | Buy Initiates $73 | Buy | Initiates | $73 | +23.27% | Sep 12, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $67 → $69 | Buy | Maintains | $67 → $69 | +16.51% | Aug 7, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +21.58% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
46.68M
from 434.43M
Decreased by -89.26%
Revenue Next Year
162.52M
from 46.68M
Increased by 248.17%
EPS This Year
-2.02
from 4.23
EPS Next Year
-0.97
from -2.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.8M | 441.0M | |||
| Avg | 46.7M | 162.5M | |||
| Low | 27.7M | 19.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -81.6% | 844.8% | |||
| Avg | -89.3% | 248.2% | |||
| Low | -93.6% | -58.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.23 | 3.83 | |||
| Avg | -2.02 | -0.97 | |||
| Low | -2.38 | -3.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.